Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
about
Glucagon and heart in type 2 diabetes: new perspectivesIncretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical EvidenceContinued efforts to translate diabetes cardiovascular outcome trials into clinical practiceCurrent perspectives on cardiovascular outcome trials in diabetes'Browning' the cardiac and peri-vascular adipose tissues to modulate cardiovascular riskHeart Failure: a Major Cardiovascular Complication of Diabetes MellitusBringing patient centricity to diabetes medication access in CanadaCardiometabolic Syndrome and Increased Risk of Heart FailureClosing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyondThe Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Both?SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.Medical Management of Diabesity: Do We Have Realistic Targets?Understanding and overcoming metformin gastrointestinal intolerance.Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.Diabetes Destiny in our Hands: Achieving Metabolic Karma.Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.The impact of antihypertensives on kidney disease.Innovative Therapeutics: Designer Natriuretic Peptides.Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential.The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory.Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg.Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study.Sex difference in the risk for exercise-induced albuminuria correlates with hemoglobin A1C and abnormal exercise ECG test findings.Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes.Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.Advances in Clinical Cardiology 2016: A Summary of the Key Clinical Trials.Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBAn Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment.Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experienceProtective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials.Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use.Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
P2860
Q26738580-4ACEA469-8B48-455B-A72B-391746AA5E65Q26739999-C27379C4-95EB-4862-A3BB-A9CA86D522D1Q26741860-7EA11507-63E5-4708-9A0F-5D77D749EE8CQ28066006-E41855E9-9B34-49D4-BB5F-DA60E1861E70Q28066261-19A21897-2D50-4D55-965B-74ED43B1A2A9Q28066310-0DDF5526-D2EE-43E3-9EE3-393A1A9623A3Q28067085-2251AF66-E359-44AD-81C2-222E046100DAQ28070075-C7C45832-AFF6-4AFC-ABF0-1E7957E83E77Q28075848-03ECB47A-F7B4-42DC-A562-E2C589505717Q28075888-62E9175D-CF2C-4021-A4AE-15C97C3C83B8Q30238791-56E7C8AB-1C42-4FDF-AEFA-680EF8948BF8Q30238940-926BB652-3F2C-4A5B-B702-022C87171773Q30240030-D212AA77-4A8F-4361-A053-38FC1BF3991FQ30240808-E1C67FC4-274E-4FAB-9003-AF242FC2BBA4Q30400748-FFE9A621-87EC-4248-AD4E-F6CEAC9D7B69Q30402492-3F52310F-2F1E-473A-AC66-2B1CF0E38EE8Q31167862-DF8C833C-97F9-47CE-A5E6-7745B293A515Q33632021-A5077297-7A3E-49B8-BD39-2AD507CDFD15Q33653332-06C4FCB4-8AE7-47A1-AC76-F7CDCBEA2CBFQ33656442-2868703D-358A-424D-BB25-E26A68F48B03Q33700894-3F285D87-D89B-4409-ACED-3A171F71BDE7Q33708984-A1B5D692-6261-48A0-83E1-FE6473E7CA86Q33709306-31D707DA-3E86-4348-858A-2D2A9711784AQ33732593-689796C1-4DDA-4993-89F3-4F289A759519Q33732627-CE340517-1599-4845-8663-DFDD15260EFFQ33750634-D29FDA5A-3FC1-4A5D-A8F0-5DBD3EA7D49EQ33775785-67C1BB10-981B-4B30-BA8C-7EA38848B830Q33814995-4B5A1F9B-F94A-4047-B12A-03E5D1E2D1B2Q33827573-EAF7C1F8-3DEE-4843-931C-3D040981307CQ33835709-A2DB110F-52E5-4168-8C5B-953A9AEC42C8Q33845734-1CDD4148-A014-4853-8223-F190475D9698Q33871304-AC6A5A1F-404B-4039-8E61-3D0BBC4C58A2Q33887783-D9C23A69-35E1-4A21-89A6-893811519328Q33890811-ADE9B623-D0F1-423F-ACFD-E9CCBB1B98E4Q33908782-CEC55C0B-D6D2-4506-A3AB-E454B567031BQ34548875-7035FEE1-E8C9-4681-B3A1-8F53146E1679Q36291168-07AC3DB3-7439-4CFF-8F8A-26D8671ABC0AQ36305825-6FBBA146-C8F7-49E2-A6B3-FD43D1EC7C67Q36316732-C6FF3848-A4AC-4272-9028-AC32AF943E45Q36341246-B04BDEA4-9BDF-41AE-BDD2-0CF9EE154A8E
P2860
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
@ast
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
@en
type
label
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
@ast
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
@en
prefLabel
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
@ast
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
@en
P2093
P2860
P356
P1476
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
@en
P2093
Gilbert H Daniels
Johannes F E Mann
Kirstine Brown-Frandsen
LEADER Steering Committee
LEADER Trial Investigators
Lasse S Ravn
Mette Stockner
Michael A Nauck
Neil R Poulter
Peter Kristensen
P2860
P304
P356
10.1056/NEJMOA1603827
P407
P577
2016-06-13T00:00:00Z